Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030 Study by ‘HTF MI’ aims to offers key information about the market stats. The report provides deep analysis about the growth drivers, opportunities, restraints, influencing trends, and challenges in the industry to help strategy planners, business owners, and individual enterprises to plan operative strategies and gain prominent position during the forecast period 2021 - 2026. The latest version of Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) report offers market share, market size, and growth rate from 2016-2026, the market segmentation is covered on the basis of product, application, technology, and geography.
Get one step closer to market leaders and emerging players of Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030 Market.
Get Sample Pages for Quick Illustration @:https://www.htfmarketreport.com/sample-report/3283880-chronic-kidney-disease-10
Summary
Chronic kidney disease (CKD), or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. In the early stages, CKD is a largely asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time (Centers for Disease Control and Prevention, 2019). As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2019). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered as the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013).
In the 7MM, the diagnosed prevalent cases of CKD are expected to increase from 8,569,869 cases in 2020 to 9,440,881 cases in 2030, at an Annual Growth Rate (AGR) of 1.01%. In 2030, the US will have the highest number of diagnosed prevalent cases of CKD in the 7MM, with 4,253,149 diagnosed prevalent cases, whereas Italy will have the fewest diagnosed prevalent cases with 339,208 cases. In the 7MM, the total prevalent cases of CKD are expected to increase from 97,176,505 cases in 2020 to 107,283,608 cases in 2030, at an AGR of 1.04%. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases and total prevalent cases of CKD to population dynamics in each market.
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed and total prevalent cases of CKD. The diagnosed and total prevalent cases of CKD are segmented by age (18 years and older), sex, and stage. The diagnosed prevalent cases of CKD are segmented based on dialysis-dependent and non-dialysis-dependent cases.
- The dialysis dependent cases are further segmented by hemodialysis-dependent and peritoneal dialysis-dependent. Additionally, the diagnosed prevalent cases of CKD were further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases. This epidemiology forecast for CKD is supported by data obtained from peer-reviewed articles and population-based studies.
- The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Make an Enquiry for Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030 Market Study @ https://www.htfmarketreport.com/enquiry-before-buy/3283880-chronic-kidney-disease-10
Reasons to Buy
The CKD Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CKD market.
- Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CKD therapeutics in each of the markets covered.
- Understand magnitude of CKD by stage, hemodialysis-dependent and peritoneal dialysis-dependent; hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases of CKD.
browse complete report and table of contents @ https://www.htfmarketreport.com/reports/3283880-chronic-kidney-disease-10
Thanks for showing interest in Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030 Market publication; you can also get Individual Chapter or Regional or Country wise report USA, GCC, Southeast Asia, North America, Europe, APAC or LATAM.
Media Contact
Company Name: HTF Market Intelligence Consulting Private Limited
Contact Person: Craig Francis
Email:Send Email
Phone: 2063171218
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: https://www.htfmarketreport.com/reports/3283880-chronic-kidney-disease-10
